The 5-year OS rates were 46% in the HIPEC group versus 38% in the no-HIPEC group, they noted in Lancet Oncology. The trial ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Individuals are managed by specialist teams, but primary care will maintain a ... of these signals and timely communication ...

Background For evaluation of breast cancer screening and informed prioritisation, it is important to examine the downstream ...

The incidence of breast cancer has increased from 900 000 to 2.3 million new annual cases over the last 25 years. The 5-year ...

The 51-year-old from Northamptonshire, in central England, was diagnosed with incurable cancer in 2015 ... he would have ...

Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...

For more information about Cellectar, please visit Cellectar.com. To learn more about SpectronRx, visit SpectronRx.com.

“The MMAI risk classifier is a more precise and accurate prognosticator of metastasis than NCCN risk groups,” Dr Tward’s team wrote. “This approach aims to prevent both overtreatment and ...

New research from ACG 2024 reveals that primary sclerosing cholangitis raises colorectal cancer risk even in patients without ...

Researchers at the Center for Genomic Regulation (CRG) reveal that metabolic enzymes known for their roles in energy ...